COMMUNIQUÉS West-GlobeNewswire

Oh!mino Survey Finds GLP-1 Muscle Loss Concerns Drive New Focus on Preserving Muscle While Dieting
09/07/2026
Seal Beach, CA, July 09, 2026 (GLOBE NEWSWIRE) -- Oh!Nutrition, a California-based nutritional product development company, has released company survey findings from more than 500 Oh!mino users taking GLP-1 medications [...]
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
09/07/2026
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes [...]
Tilray Medical Announces Commercial Launch of Medical Cannabis in Panama, Expanding Patient Access Across Latin America
09/07/2026
Launch of Tilray Medical's first medical cannabis product in Panama strengthens the company's international footprint and supports broader access to regulated cannabinoid-based medicines PANAMA CITY, July 09, 2026 ( [...]
Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
09/07/2026
Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development [...]
Amneal to Report Second Quarter 2026 Results on July 30, 2026
09/07/2026
BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Thursday, July 30, [...]
Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
09/07/2026
This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases WALTHAM, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: [...]
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
09/07/2026
PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/07/2026
BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today [...]
Breckenridge Distillery Launches Breck Vodka Seltzer, a Crisp New Ready-to-Drink Line Born in the Rockies
09/07/2026
The Award-Winning Colorado Craft Distillery Enters the Vodka Seltzer Category with Four Refreshing Flavors at 5% ABV BRECKENRIDGE, Colo., July 09, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery , one of the most- [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2026
09/07/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
GUERBET : Bilan semestriel du contrat de liquidité
09/07/2026
Bilan semestriel du contrat de liquidité Villepinte, le 9 juillet 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, présente aujourd’hui le bilan [...]
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
09/07/2026
Data Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 - Dosing of additional patients in Cohort 1 is underway at sites in the US and [...]
SRX Global Board of Directors Authorizes Stock Repurchase Plan of Up to 10 Million Shares or Up to 50% of its Shares Outstanding
09/07/2026
NORTH PALM BEACH, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments [...]
Ipsen - June 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
09/07/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Juin 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
09/07/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
09/07/2026
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built with [...]
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
09/07/2026
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus ® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to [...]
Heald Expands Access to AI-Powered Glucose Intelligence for Over-the-Counter CGM Users
09/07/2026
Consumers purchasing Dexcom Stelo or Abbott Lingo through Heald now receive complimentary access to AI-powered glucose insights ALPHARETTA, Ga., July 09, 2026 (GLOBE NEWSWIRE) -- Heald, a digital metabolic health [...]
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
09/07/2026
Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing First-Ever [...]

Pages